Crossref Metadata :  
ISSN Online :  Under Processing
Journal DOI :  10.31579/JHRAT/2018
Google Scholar :   Citation
Current Issue :  Volume 2 - Issue 1 - 2019
PubMed Indexed Articles :  
Email :
Indexing :  

HIV AIDS Research and Antiviral Therapy : Open Access

About the Journal

Journal of HIV/AIDS Research and  Antiviral Therapy (JHRAT) is a multidisciplinary international peer-reviewed open access journal, which provides a display place for researchers, clinicians, scientists and practitioners all over the globe to encourage, share, instigate the modern developments and research work in diagnostics and therapeutics invented to prolong the lifespan and recover the quality of health for HIV/AIDS patients.
An international delegation on the editorial board will support to deliver the quality work all over the world and Elucidate international advances in study, practice, and research, with a single common objective to reduce suffering and maintain excellence in the healthcare of patients throughout the world.
JHRAT delivers the newest technology in experimental and social behavior built investigations in HIV/AIDS and other sexually transmitted contagions, by publishing the research articles of high quality by undergoing rigorous standard double-blinded peer review process with expert reviewers and editorial board members.
JHRAT implements the Creative Commons Attribution License to all works published providing instant and permanent access for free to all types of original works. The license grants copyright to the author concerned and makes the articles available for their dissemination. Anyone can use the articles in any constructive way as long as the credit is given to the author and citation to the original source.
JHRAT editor welcomes researchers, clinicians, scientists from all parts of the globe to publish original articles, reviews, case reports, short communications, editorials, commentaries, and letters.

The Journal is using double-blind peer-review for the manuscript processing. Each article undergoes this peer review process under the aegis of an assigned Editor. To be acceptable for publication, an article should be positively considered by two individual reviewers followed by the Editor’s consent.


An agent that kills a virus or that suppresses its ability to replicate and, hence, inhibits its capability to multiply and reproduce.

 These are medications that reduce the ability of flu viruses to multiply. The CDC considers antiviral drugs as a "second line of defense against the flu" after getting an annual flu vaccine.

 Most antivirals are considered relatively harmless to the host, and therefore can be used     to treat infections.The development of antivirals has lagged far behind that of antibiotics. A virus is just genetic material, DNA or RNA, perhaps with a few enzymes, wrapped in a protein coat. A viral is technically not alive which makes it hard to kill. Further, viruses replicate (make copies of themselves) by hijacking the machinery of the cell they infect, so it is difficulty to kill the virus without killing the cell. Some viruses can also remain dormant in the body without replicating, thereby avoiding drugs that inhibit replication.

Mechanisms of Action of Antiviral Agents

Viral infections are initiated when virions attach to host cells. Attachment is mediated by capsid- or envelope-related viral proteins that bind specific receptors on host cell membranes. For example, the HIV envelope contains glycoproteins that mediate binding of the virus to CD4+ T lymphocytes that express CCR5 and/or CXCR4 receptors. A currently available inhibitor of viral attachment blocks HIV-specific CCR5 receptors on CD4+ T cell membranes.

Antiviral Targeting

The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. These "targets" should generally be as unlike any proteins or parts of proteins in humans as possible, to reduce the likelihood of side effects. The targets should also be common across many strains of a virus, or even among different species of virus in the same family, so a single drug will have broad effectiveness.

One anti-viral strategy is to interfere with the ability of a virus to infiltrate a target cell. The virus must go through a sequence of steps to do this, beginning with binding to a specific "receptor" molecule on the surface of the host cell and ending with the virus "uncoating" inside the cell and releasing its contents. Viruses that have a lipid envelope must also fuse their envelope with the target cell, or with a vesicle that transports them into the cell.

Journal Highlights :

Anti-retroviral therapy


Vaccine development


Epidemiology of HIV

Viral targets

Viral genetic variability

Health economics and public health policy

Diagnosis of HIV/AIDS

Epidemiology of HIV/AIDS

Opportunistic infections in HIV/AIDS

Clinical Virology

Combination Therapy


Emerging Viral Diseases

Viral Vaccine

Protease Inhibitors

Interferons (IFNs)


Pathogenicity of HIV/AIDS

Political Economy of HIV Infection/AIDS

Prevention of HIV/AIDS

Treatment of HIV/AIDS

Virology immunology of HIV/AIDS

Substance abuse





Systematic review




Advances in HIV Diagnosis

Advances in HIV Medications

Drug Resistance of HIV

HIV Vaccines

Innovative HIV drugs

Risk Analysis: HIV

Risk Behaviours of HIV/AIDS

Antiretroviral therapy

Antiviral therapy

AIDS Dementia Complex

HIV Super Infection

Genome of HIV


Epidemiology of HIV

Paediatric HIV and AIDS

Immunology of HIV/AIDS

Viral load

Therapeutic Vaccines

Advances in HIV Tests

HIV Replication

Highly Active Antiretroviral Therapy

HIV Retrovirus

Advances in HIV Treatment

HIV Super Infection

Drug Clinical Trials

HIV Clinical Trials

Human Retro-virology

Antiretroviral Treatment

HIV Diagnostics

HIV Wasting Syndrome

Vaccine Research in HIV

Highly Active Antiretroviral Therapy